-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
2025-09-10
“City of Happiness, Labor Is the Most Beautiful” Team Diary | Shijiazhuang No. 4 Pharmaceutical Liquid Formulation R&D Team: Crafting Quality Medicines with Artisan Spirit, Safeguarding Health Through Innovation
On the battlefield of pharmaceutical R&D, there is a dedicated group of individuals who make the laboratory their stronghold and harness their ingenuity to break through technological barriers. Today, we step into Shijiazhuang Sihua Pharmaceutical to meet the Liquid Formulation R&D Team—a team that safeguards human health with both wisdom and hard work—and to explore their unwavering commitment to excellence on the path of pharmaceutical innovation.
2025-08-02
Shijiazhuang Daily | Reading the Data, Seeing the Development | In the First Half of the Year, Shijiazhuang’s Value Added by Industries Above Designated Size Recorded Double-Digit Year-on-Year Growth—What Transformative Breakthroughs Do These Striking Figures Reflect?
On July 26, at the Analytical Center of the Pharmaceutical Research Institute of Shijiazhuang Sihua Pharmaceutical Group, more than 100 high-performance liquid chromatographs were neatly arranged and operating at full speed, while researchers at the computer workstations outside the floor-to-ceiling glass windows were intently sorting through real-time experimental data being transmitted.
2025-05-22
Hebei Daily | “AI Empowers Thousands of Industries: Firsthand Stories | Visual AI Acts as a ‘Supervisor,’ While Algorithms Serve as ‘Strategists’ in Drug Screening”
Recently, at Workshop 312 of Shijiazhuang Sihua Pharmaceutical Group, the upright soft-packaging production line for large-volume injectables has been operating at a rate of 400 vials per minute. Vial after vial of injectable solution “runs” into the “darkroom,” where strobe lights flash rapidly.
In early summer, all things are lush and teeming with vitality. In the laboratories of the Hebei Provincial Research Institute of Sterile Pharmaceutical Preparations Technology, rows of test tubes are neatly arranged on the workbenches, while researchers meticulously operate equipment and record analytical data.
21
2025/05
On a spring day in Shijiazhuang, sunlight streams through the Venetian blinds into the laboratories of the Pharmaceutical Research Institute of Shijiazhuang Sihua Pharmaceutical Group. On the lab benches, rows of test tubes refract a glistening halo, as researchers meticulously operate instruments and record analytical data.
10
2025/04
Hebei Daily | “Orphan Drugs” — Not Alone
Stiripentol dry suspension is an “orphan drug” exclusively manufactured in China, developed by Shijiazhuang Sihua Pharmaceutical Group, and indicated for the treatment of refractory epilepsy in children. In the first quarter of this year, this orphan drug was introduced into more than 100 Grade-II-A or higher medical institutions in Beijing, Shanghai, Zhejiang, and other regions, achieving strong sales performance.
10
2025/04
In recent days, all levels and departments in Shijiazhuang have thoroughly studied and implemented General Secretary Xi Jinping’s important expositions on the development of the private sector and the spirit of his important speech at the symposium on private enterprises. They have earnestly carried out the decisions and arrangements made by the CPC Central Committee and the State Council, as well as by the provincial Party committee and provincial government and the municipal Party committee and municipal government, to promote the high-quality development of the private economy. Efforts have been continuously intensified to further optimize the business environment, address the financing challenges faced by private enterprises, and support their innovation and development, resulting in a steadily improving environment for the growth of the private sector and enabling a large number of private enterprises to achieve new leaps and new developments.
26
2025/03
“The Provincial Government Work Report outlines eight priority areas for 2025, the first of which is to concentrate on developing new-quality productive forces and building a modern industrial system. Notably, this section specifically emphasizes bolstering the biopharmaceutical industry, which has further strengthened our confidence as a pharmaceutical company in pursuing R&D-driven innovation and integrated “API-plus-formulation” development.” On the afternoon of January 16, Su Xuejun, a deputy to the Hebei Provincial People’s Congress and Chairman of Shijiazhuang No.4 Pharmaceutical Co., Ltd. (hereinafter referred to as “Shijiazhuang No.4”), who had just returned to work after attending the Two Sessions of Hebei Province, promptly conveyed the spirit of the sessions to the grassroots level and ensured its effective implementation.
23
2025/01
Since the beginning of 2025, nearly half a month has passed, during which various regions and departments have formulated new strategies and implemented concrete measures. Across all sectors, proactive efforts are being made to embrace innovation and pursue new opportunities, with tailored approaches to developing new-quality productive forces and unleashing fresh momentum for growth. By leveraging innovation to drive development and capitalizing on distinctive strengths to capture market share, a robust wave of new-quality productivity is steadily gaining traction, painting a new picture of China’s economy.
17
2025/01
“While vigorously developing the biopharmaceutical industry, we must never overlook active pharmaceutical ingredients, as they are the ‘chip’ of the biopharmaceutical sector,” said Su Xuejun, a representative to the Hebei Provincial People’s Congress and Chairman of Shijiazhuang Sihua Pharmaceutical Co., Ltd. (hereinafter referred to as “Shijiazhuang Sihua”), on January 13.
17
2025/01
At the start of the year, driven by technological innovation, Hebei Province is witnessing robust growth in new-quality productive forces, with ongoing efforts to intelligently upgrade and digitally transform traditional industries, yielding new advances and a fresh outlook across multiple sectors.
15
2025/01
Yanzhao Evening News | Tong Qiaolin: Cities Respect Talent, and Talent Repays the City
Stepping into the API R&D laboratory of the Pharmaceutical Research Institute at Shijiazhuang Sihua Pharmaceutical Co., Ltd., Tong Qiaolin, a post-1980s researcher, is leading his team in intensive work.
02
2025/01
“Champion, Show Us Your Skills” | Bai Xue: In my line of work, “close enough” simply doesn’t exist!
On the evening of December 6, Hebei TV’s “Hebei News Broadcast” aired the third episode of “Champions Show Their Skills,” introducing Bai Xue, the champion of the Injectable Preparations Competition at the 2024 Hebei Provincial Workers’ Vocational Skills Contest and a pharmaceutical solution preparer in Workshop 208 of Shijiazhuang Sihua Pharmaceutical Group.
11
2024/12
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091